Biparatopic HER2-targeted nanobody binder synergizes with trastuzumab in resistant tumor cells
Human epidermal growth factor receptor 2 (HER2) is a key oncogenic driver in diverse solid tumors. Although HER2-targeted therapies such as trastuzumab and pertuzumab confer substantial clinical benefits, therapeutic resistance remains a major challeng…